Guide for Authors
The primary emphasis of the journal will be clinical and to this end, a number of different types of articles will be published. Each type will be aimed to provide clinically important information needed to keep up to date with the practice of sleep medicine, written in a way to foster interdisciplinary understanding and make clinical information accessible to all practitioners.
This journal offers you the option of making your article freely available to all via the ScienceDirect platform. To prevent any conflict of interest, you can only make this choice after receiving notification that your article has been accepted for publication. The fee of $3,000 excludes taxes and other potential author fees such as color charges. In some cases, institutions and funding bodies have entered into agreement with Elsevier to meet these fees on behalf of their authors. Details of these agreements are available at http://www.elsevier.com/fundingbodies. Authors of accepted articles, who wish to take advantage of this option, should complete and submit the order form (available at http://www.elsevier.com/locate/openaccessform.pdf). Whatever access option you choose, you retain many rights as an author, including the right to post a revised personal version of your article on your own website. More information can be found here: http://www.elsevier.com/authorsrights.
Sleep Medicine publishes the following types of articles:
•Original articles dealing with diagnosis, clinical features, pathophysiology, etiology, treatment (by all relevant modalities, including pharmacological, instrumental, surgical, behavioral, nutritional), genetics, epidemiology, natural history and prognosis of human sleep disorders will be considered for publication, provided these have not been previously published except in abstract form or have not been submitted simultaneously elsewhere. Reports may also include technical aspects of sleep medicine, which are relevant for diagnosis, pathophysiology, etiology, treatment and natural history. Basic research articles will also be published where they have a direct impact on or shed considerable light on clinical aspects of sleep. Submission of original articles based on animal or human experimental studies are encouraged, and these articles should include a comment in the abstract and discussion about the potential clinical relevance of the study.•Clinical Trials in Sleep Medicine The modern area of medicine was heralded by the execution of placebo controlled clinical trials. In that vein it is important to recognize that further advances in sleep medicine are, in part, dependent on future randomized clinical trials. For example, double blind controlled trials on efficacy of CPAP on waking and cardiovascular functioning and behavioral and pharmacological therapies addressing multiple types of insomnia populations using novel therapeutic endpoints will help define the future of sleep medicine therapeutics. To foster the rapid dissemination of the results of these trials, Sleep Medicine will rapidly review and publish clinical trials addressing any sleep or sleep related disorders.
The members of the Editorial Board at their last meeting in Quebec City, Canada during the 4th WASM Congress discussed the question of clinical trial registration for all randomized controlled trials. The International Committee of Medical Journal Editors (ICMJE) has adopted a position that requires, as a condition of consideration for publication of clinical trials, registration in a public trials registry. In line with this position, many journals now require a Consolidated Standards of Reporting Trials (CONSORT) statement http://www.consort-statement.org at submission of a manuscript based on the trial. The Editorial Board mentioned that different countries have different regulatory requirements. A standardized registration system is available in the United States, the European Union (Western Europe), Japan, Canada, and Australia. Many clinical trials now take place in Asia, Eastern Europe, Central America, and South America where there is no compulsory registration system and no requirement for registration. The Sleep Medicine editorial board, therefore, decided on a modification of such reporting. For those countries where there may not be such a requirement, the statement should say that there is no such requirement or state the equivalent registration requirement for a particular country.•Review articles on all aspects of clinical sleep medicine and related basic science that contribute to understanding clinical sleep medicine will be published. Reviews will be timely, emphasize areas undergoing new development, and include both state of the art reviews and multi-author discussion of controversial areas.
•Controversies in sleep medicine covering dissenting views (pros and cons) will be published periodically.
•Editorials on manuscripts published elsewhere in the journal or on a timely and controversial topic will be published occasionally. Editorials may contain up to 1000 words and 20 references.
•Preliminary or limited results of investigations will be published as brief communications (up to 1500 words containing 20 or fewer references, one table and one figure).
•Letters to the Editor addressing articles appearing in the journal or on other current topics will be published (up to 300 words and five references).
The journal will publish special issues or supplements dealing with proceedings of meetings, workshops or special topics.
•Medical Hypothesis providing an opportunity to address testable hypotheses in sleep medicine based on solid scientific foundation will be considered for publication.
•Historical Issues in Sleep Medicine submissions dealing with sleep-related historical figures, whether leaders from the past or characters from literature or mythology, will be considered for publication.
•Book reviews are also published. Upon reception of a book from the publisher, it is sent to the book review editor.
•Images in Sleep Medicine submissions should derive from a specific sleep-related clinical situation. Each submission must consist of high-resolution images (e.g. polysomnographic tracing, actigraphic recording, neuroimaging, etc.) and should be accompanied by a very brief clinical impression, significance of the findings and figure legend. Readers will be encouraged to foster discussion of any controversial images. Submissions may contain up to 500 words and five references, and content must be organized by the following headings: 1. Introduction to the case, 2. Image analysis, 3. Discussion, and 4. References. Submissions not adhering to these guidelines may be rejected without further consideration.
•Clinical Corners will deal with complex and unusual cases of sleep disorders and seek comments from readers about these cases. We invite potential authors to submit interesting clinical material to this section.
•Special Sections, which focus on such topics as education, guidelines, etc., are published intermittently.
•Video-Clinical Corners will deal with interesting and challenging clinical cases and significant original phenomena. Every video submission must consist of high-resolution images and a consent form for publication for educational purposes signed by the patient see form, please see the Patient Details section below. The Editors reserve the right to ask for additional video/s or video modifications. Submissions may contain up to 750 words, 10 references and 2 figures, and content must be organized as follows: 1) Introduction of the case stating the purpose and unusual and interesting aspects of the video; 2) Case description including chief complaint, past and present medications and history and physical findings; 3) Video analysis of data including representative examples from the patient's polysomnogram; 4) Brief discussion of the differential diagnosis and therapeutic challenge.
For tips on preparing your video for submission, see here•Sleep medicine also intermittently publishes articles in WebWatch, a section which highlights Internet sources containing information on sleep medicine.
•Also published in the journal are News and Announcements and an International Calendar pertaining to events in sleep medicine.
Patient DetailsThe author is responsible for obtaining all necessary consents from patients for (i) the performance of any medical procedure involved, as well as (ii) a release permitting our use of the relevant material. It is our insurers' preference that we do not have any direct contractual relationship with the patients themselves. Please download the Patient consent form here.
Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in your paper.
If you wish to include images of patients or case details in an Elsevier publication, you will need to adhere to the following requirements:
In order to comply with data protection and privacy rules, each individual who appears in any video, recording, photograph or case report must be made aware in advance of the fact that such photographs are being taken or such video, recording or report is being made and of all of the purposes for which you wish to use them and that individual (or next of kin in the case of children) must give his/her explicit written consent. If such consent is made subject to any conditions (for example, adopting measures to prevent personal identification of the person concerned), Elsevier must be made aware of all such conditions. Written consents must be provided to Elsevier on request.
Fast Track PublicationThe journal is published bi-monthly and all manuscripts are peer-reviewed except proceedings of scientific meetings.
Articles for 'fast track publication' can be submitted provided they fulfil the criteria of containing new and important scientific information. Articles for 'fast track publication' if accepted will be published within 8 weeks from the received date at Elsevier. Such manuscripts should not exceed 2000 words, 20 references and 3 illustrations or tables. The Editors reserve the right for final decision whether a manuscript submitted for fast track publication will be so processed or be submitted through the routine review process.
Electronic submission via the Web using EESSleep Medicine uses an online, electronic submission system called EES (Elsevier Editorial System). By accessing the following website http://ees.elsevier.com/sleep
The preferred medium of submission to the accepting Editor is online with the accompanying manuscript, illustrations, tables and annexes. Submission of a paper to Sleep Medicine is understood to imply that it has not previously been published (except in abstract form) and that it is not being published elsewhere. Submitted manuscripts should be accompanied by a statement undersigned by all listed authors that they concur with the submission and that the manuscript has been approved by the responsible authorities where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form in either the same or any other language, without the consent of the Editor and Publisher. The decision of the Editor is final. The Editor cannot enter into correspondence about a paper considered unsuitable for publication.
You will be guided stepwise through the creation and uploading of the various files. When submitting a manuscript to EES, authors need to provide an electronic version of their manuscript. The author should select a set of classifications from a list, a category designation for their manuscript (original article, review, controversies, letter to the editor, brief communication, etc.) and may provide keywords and comments to the Editor separately. Details of two reviewers may be suggested with a submission and can be provided in the comments box or at a later stage when uploading the files for submission.Authors may send queries concerning the submission process, manuscript status, or journal procedures to the Editorial Office (email@example.com). Once the uploading is done, the system automatically generates an electronic (PDF) proof, which is then used for reviewing. All correspondence, including the Editor's decision and request for revisions, will be by e-mail.
Changes to authorshipFunding body agreements and policies
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed. After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.
Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies
Manuscript PreparationColour Reproduction
Use double spacing throughout, including the reference section. Manuscripts should be organized as follows: Title page, Abstract, Introduction, Methods, Results, Discussion, References, Legends, and Tables and Figures.
Authors' full names, academic or professional affiliations, and complete addresses must be included on the title page. The corresponding author must be indicated by an asterisk, and his/her full contact details must be included (telephone and fax numbers and e-mail address).
A structured abstract of approximately 200 words is mandatory at the beginning of each article. The abstract should be organized by: Objective or Background, Methods, Results, and Conclusions. Review articles and case reports do not need a structured abstract.
6-8 items must be included on the title page. Authors are encouraged to choose their own key words, but Medical Subject Headings (issued with the January Index Medicus, latest edition) may be used as a guideline.
References to literature must be indicated by Arabic numerals which run consecutively through the paper. Where a reference is cited more than once in the text the same number should be used each time. Reference style should follow the "Vancouver" style described in the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (published in N Engl J Med 1997;336:309-315). The titles of journals should be abbreviated in conformity with Index Medicus. The following are sample styles:
 Bondi M, Kaszniak A. Implicit and explicit memory in Alzheimer's disease and Parkinson's disease. J Clin Exp Neuropsychol 1991;13:339-358.
 Wechsler D. Wechsler Adult Intelligence Scale. New York: Grune & Stratton, 1976.
 Hirst W, Volpe B. Automatic and effortful encoding in amnesia. In: Gazzaniga M, editor.
Handbook of cognitive neuroscience. New York: Plenum Press, 1984; p. 369-386.
Please ensure that references are complete, i.e. that they include, where relevant, the author's name, article or book title, volume and issue number, publisher and publisher's location, and page reference.
This journal should be abbreviated as Sleep Med.
Figure and Table Legends
Legends should be typed double spaced on a separate page and numbered with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers or letters are used to identify parts of the illustrations, each should be explained clearly in the legend. The legends should permit the figures to be understood with reference to the text. If the figure has been published previously a credit line should be included.
Figures of good quality should be submitted online as a separate file. Letters, numbers and symbols should be clear throughout and should be large to permit photographic reduction.
Be sure that all spelling is correct, that there are no broken letters or uneven type, and that abbreviations used are consistent with those in the text. Use a label on the back of each figure to indicate the article's running title and the top of the figure. Do not write directly on the back of photographs. Do not trim, mount, clip or staple the illustrations. Submit photomicrographs in the final desired size. The colour transparency or negative should be supplied, in addition to colour prints.
Photographs of recognizable persons should be accompanied by a signed release from the patient or legal guardian authorizing publication. Masking eyes to hide identity is not sufficient.
For colour reproduction in print, a limited number of colour figures may be printed in the Journal without cost, at the discretion of the Editor, who will make the judgement based on the academic necessity of the colour illustrations. Otherwise you will receive information regarding the costs from Elsevier after receipt of your accepted article. For further information on the preparation of the electronic artwork, please see http://www.elsevier.com/artworkinstructions
TablesPreparation of Supplementary Material (MultiMedia Components)
Tables should be submitted online as a separate file and should bear a short descriptive title. If a table must exceed one typewritten page, duplicate all headings on the second sheet. Number tables in the order in which they are cited in the text. Every column in the table should have an abbreviated heading. Define all abbreviations and indicate the units of measurements for all values. Explain all empty spaces or dashes. Indicate footnotes to the table with the superscript symbols cited in order as you read the table horizontally.
Elsevier now accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, movies, animation sequences, background datasets, sound clips and more.
Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier web products, including ScienceDirect (http://www.sciencedirect.com). In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file formats. Files can be stored on diskette, ZIP or Jaz-disk, or CD or DVD (either MS-Windows or Macintosh). Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit http://elsevier.com/authors.
We have successfully negotiated with eight language editing companies to provide language editing services to our authors at competitive rates. American Journal Experts, Asia Science Editing, Diacritech Language Editing Services, Edanz Editing, International Science Editing, ScienceDocs Editing Services and SPI Publisher.
Services provide language and copy editing services globally to authors who wish to publish in scientific, technical and medical peer-reviewed journals and would like assistance either before they submit an article for peer review or before it is accepted for publication.
Use of an English-language editing service listed here is not mandatory, and will not guarantee acceptance or preference for publication in an Elsevier journal. Please note: Elsevier neither endorses nor takes responsibility for any products, goods or services offered by outside vendors through our services or advertised on this website.
Please go to: http://www.elsevier.com/wps/find/authors.authors/languagepolishing for more information.
Proofs will be sent to the first-named author of an article unless an alternative is requested on the title page of the manuscript. They should be checked carefully and returned to the publisher by airmail within 2 days of receipt. Only typesetting errors may be corrected: no changes in or additions to the edited original manuscript will be allowed at this stage.
Reprints may be ordered by completing and returning to the Publisher the order form sent with the proofs. 25 free reprints per contribution will be made available.
Queries about a manuscript after its acceptance, especially those relating to proofs, publication and reprints, should be directed to: Elsevier Ireland Ltd., Elsevier House, Brookvale Plaza, East Park, Shannon, Co. Clare, Ireland. Tel. (+353) 61-709-600; Fax: (+353) 61-709-100, specifying Journal title and Editor's code/manuscript number.
Declaration of HelsinkiConflict of Interest
Articles dealing with human experiments must conform to the principles enumerated in the Helsinki Declaration of 1975, and must include a statement that informed consent was obtained after full explanation of the procedure.
NOTE TO CORRESPONDING AUTHORSThe ICMJE* Uniform Disclosure Form for Potential Conflicts of Interest must be downloaded and sent to all co-authors. Completed forms from ALL authors must be uploaded as one file along with your submission. The form can be found in the 'Attach Files' section of the submission process. Please be advised: It is the expressed wish of the editorial board not to accept ghost written articles; it is the responsibility of the senior author to enforce this policy. A link to the disclosure forms will be added to all accepted articles.*International Committee for Medical Journal Editors http://www.icmje.org/.
IRB approvalPhase III Trials
If applicable, a statement must appear in the Methods section that the study was approved by the relevant institutional review boards, ethics committees, or similarly authorized bodies overseeing the research proposals.
Manuscripts reporting the results of Phase III trials must follow the Consolidated Standards of Reporting Trials (CONSORT) guidelines. For more information on these guidelines, please refer to:
Begg, C, Cho, M. Eastwood, S, et al. Improving the quality of randomized controlled trials: the CONSORT statement. JAMA 1996; 276:637-639.
Schulz, KF. The quest for unbiased research: Randomized clinical trials and the CONSORT reporting guidelines. Ann Neurol 1997; 41:569-573.
Informed Consent/Ethics of ExperimentationPurpose and Procedure
Studies on patients or volunteers require ethics committee approval and informed consent which should be documented in your paper.
Patients have a right to privacy. Therefore identifying information, including patients' images, names, initials, or hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable). If such consent is made subject to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to Elsevier on request.
Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.
If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission.
Articles submitted for review should meet the following criteria:
•Studies of prevention or treatment must meet these criteria: random allocation of participants to comparison groups; follow-up of at least 80% of those entering the investigation; outcome measure of known or probably clinical importance.
•Studies of prognosis must meet these additional criteria: inception cohort of individuals, all initially free of the outcome of interest; follow-up of at least 80% of participants until the occurrence of a major study end point or to the end of the study.
•Studies of causation must meet these additional criteria: clearly identified comparison group for those at risk for, or having, the outcome of interest (e.g. randomized controlled trial, quasi-randomized controlled trial, nonrandomized controlled trial, cohort analytic study with case-by-case matching or statistical adjustment to create comparable groups, case-control study); blinding of observers of outcome to exposure (criterion assumed to be met if outcome is objective, e.g. all-cause mortality, objective test); blinding of observers of exposure to outcomes for case-control studies OR blinding of subjects to exposure for all to be compared on the basis of both the outcomes produced (effectiveness) and resources consumed (costs); evidence of effectiveness must be from a study (or studies) that meets the above-noted criteria for diagnosis, treatment, quality assurance, or a review article; results should be presented in terms of the incremental or additional costs and outcomes of one intervention over another; where there is uncertainty in the estimates or imprecision in the measurement, a sensitivity analysis should be done.